The Production of an Anti-PCHD1 Monoclonal Antibody for the Purpose of Combating Hantavirus

Overview

Hantaviruses, a group of RNA viruses, pose a significant threat to humans all around the world. Infection can cause severe consequences, including the fatal hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome. In light of the lack of effective treatment options, this project focuses on developing an anti-PCDH1 monoclonal antibody to combat hantavirus infections. The antibody is created through plasmid manipulation and Expi-CHO cell transfection. The transformation process involves introducing plasmids encoding the antibody's heavy and light chains into competent E. coli cells, followed by quality control measures. After successful transfection into Expi-CHO cells, a 10-day culturing period allows for antibody production. The purification process, using protein A sepharose beads, isolates the antibody from cellular components. Quality check methods including gel ele ctrophoresis and ELISA assays confirm the antibody's production and specificity in binding to the PCDH1 receptor. This anti-PCDH1 antibody presents a potential solution to disrupt hantavirus infections. Future steps involve testing its efficacy in a BSL3 lab and evaluating its antiviral activity in live animal models, marking a significant advancement in hantavirus treatment.

Competition history

• JSHS 2024 Category not listed

Resources

• National JSHS abstract book ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.